Omeros has spent three decades as a clinical-stage complement shop and has now crossed into a real product company. The Food and Drug Administration approved YARTEMLEA, a monoclonal antibody against MASP-2, late last year for transplant-associated thrombotic microangiopathy, a frequently fatal clotting injury after stem-cell transplant. Net product sales were $28.5 million in the first full selling quarter. That print is the first evidence that the United States launch can more than cover the operating base. The investment debate is whether the quarter is the start of a self-funding orphan franchise or a burst of hospital stocking that fades once the easy accounts are in.
The tension sits in three places at once. Reported net income looks like a turnaround, but most of the year-to-date profit is a non-cash mark on the convertible derivative rather than cash earned from vials. Adjusted earnings were only $2 million after stripping those marks. Europe delivered a negative opinion on the same data set that won United States approval, so the geographic option is now a re-examination rather than a second market. Management then spent a large slice of the $132 million quarter-end cash pile buying convertibles at a premium, which cuts dilution and coupon but shrinks the cushion just as selling costs and research spend rise.
The next several quarters resolve whether center conversion and reimbursement deepen the ramp. Unique ordering accounts more than doubled in three months, yet more than half of United States transplant centers have still not placed an order. A permanent billing code is already live and an inpatient add-on payment starts in October. If reorders and new-center adds hold after those reimbursement tools land, the launch can fund the mid-decade cash-flow goal. If they stall, the remaining convertible, the OMIDRIA royalty stack, and an unused at-the-market shelf become the funding story again.